Early-Stage Hodgkin Lymphoma: New Lessons from an Old Study

A cure rate of ≥90% for patients with early-stage Hodgkin lymphoma (HL) is routinely achieved with current regimens. But this success is tempered by the risk for late-onset morbidity and mortality associated with the initial treatment. Previously, researchers conducted a multicenter, prospective, randomized, controlled trial to compare the use of 4 to 6 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) or 35 Gy subtotal nodal irradiation (STNI) in newly diagnosed patients with nonbulky stage I or II HL …